PubMed Health⌕ Search

Biomedical subjects

J Rygård

Publications and source records attributed to J Rygård.

At least 19 recordsLinked to original sources
PubMed1983

A randomized study of radiotherapy versus radiotherapy plus chemotherapy in stage I-II non-Hodgkin's lymphomas.

In a randomized, prospective trial from 1974-1978, 73 patients with non-Hodgkin's lymphomas in clinical Stage I or II were treated with extended field radiotherapy alone (RT) or RT plus adjuvant chemotherapy with vincristine, streptonigrin, cyclophosphamide and prednisone (RT + CT). With a median follow-up time of five years, 54% have relapsed in the RT group versus only 10% in the RT + CT group (P less than 0.01). There is no statistical difference in the overall survival yet, but 13/14 deaths in the RT group versus only 3/12 in the RT + CT group were due to progressive disease. Among patients with unfavorable histology, 13/22 in the RT group have died from disease progression against 3/34 in the RT + CT group (P less than 0.01). The results are in agreement with those from two other series published in detail. Based on these results we therefore recommend to use adjuvant CT with RT in all Stage I-II patients with unfavorable histology. Further observation is necessary before a conclusion can be drawn for the lymphoma patients with more favorable histology.

Antineoplastic Agents↗
PubMed1980

Prophylactic irradiation in bronchogenic small cell anaplastic carcinoma. A comparative trial of localized versus extensive radiotherapy including prophylactic brain irradiation in patients receiving combination chemotherapy.

A total of 114 patients with bronchogenic small cell anaplastic carcinoma and staged as having regional disease all underwent combination chemotherapy consisting of CCNU, cyclophosphamide, and methotrexate. They were randomized to receive either radiotherapy to the primary tumor and regional lymph nodes (4000 rad) or extensive radiotherapy, which included the brain, adrenals, and upper retroperitoneal lymph nodes. Fifteen patients were free of disease after 18 months of chemotherapy and the treatment was discontinued. Only 3 patients subsequently relapsed. No difference was observed between the two groups of patients in median survival time, response rate, duration of response or relapse pattern, including the frequency of brain metastasis.

Adult↗
PubMed1979

Bleomycin as adjuvant in radiation therapy of advanced squamous cell carcinoma in head and neck.

Since 1969, Bleomycin (BLM) has been used in three different ways at the Radium Centre in Copenhagen. First BLM given as the sole treatment led to complete regressions in 12% of 138 patients (12). Secondly BLM was used as simultaneous adjuvant in radiation therapy for 86 previously untreated patients, but 66% developed mucositis which disrupted the treatment. In a third period BLM was therefore combined sequentially with radiation, administered for 2 weeks prior to radiation therapy to 142 patients. The tumour shrinkage achieved with preirradiation BLM was very pronounced in 38% of cases. 104 patients with T3 tumours have been observed for a minimum of 3 years. The medium survival time, 47 months for those sequentially treated patients responding pronouncedly to BLM, was greater than for the remainder of the sequentially treated patients, 16 months (2 p = 0.010) and for the patients treated simultaneously with BLM, 15 months (2 p = 0.013). The prognostic value of the degree of shrinkage achieved with preirradiation BLM treatment is discussed.

Aged↗
PubMed1977

Radiation therapy of squamous carcinoma of the floor of mouth and the lower alveolar ridge.

Treatment for 139 patients with squamous carcinomas in the floor of mouth and the lower alveolar ridge, which accounted for one-third of all patients with intra-oral cancer, are evaluated and classified after UICC and AJC's TNM recommendations retrospectively, for cancer staging and End Result Reporting. The figures include 50% women with tumours and in lower alveolar ridge. Two treatment schemes: external cobalt irradiation and external irradiation in combination with intra-oral radium-mould have been used in spite of primary bone invasion. 30% had remnant tumours and 22% recurred locally. 70% of the recurrences were discovered within a year after treatment. The total crude survival for all patients was 32%, identical for both groups. Lymph node metastases lower the survival significantly. Less than one-third had difficulties in mucous healing after treatment and 9% developed osteoradionecrosis, but only half of those patients had symptoms.

Aged↗
PubMed1973

[Lip cancer].

Explore the source record for details and available documents.

Aged↗
PubMed1972

[Mouth neoplasms].

Explore the source record for details and available documents.

Basal Cell Carcinoma↗